ONDINE
BIOMEDICAL INC.
("Ondine
Biomedical", "Ondine" or the "Company")
Appointment of Interim Chief Financial Officer
Ondine Biomedical Announces the Appointment of
Kwong Choo as Interim Chief Financial Officer
Ondine Biomedical Inc. (LON: OBI), the
Canadian Life Sciences company pioneering
light-activated antimicrobial treatments,
announces the appointment of Kwong Choo as Interim Chief Financial
Officer, following the resignation of previous CFO J. P.
Errico.
Mr. Choo, CPA, CIMA, brings more than
15 years of experience in international public
companies on NASDAQ, the Toronto Stock Exchange, and the TSX
Venture Exchange, as well as with a number of private biotechnology
and pharmaceutical companies. Mr. Choo has been working with Ondine
since 2022.
Nikita Parkhaev CPA has been appointed as Vice
President, Finance. Mr. Parkhaev most recently held the position of
Controller at Ondine. Elaine Lei CPA has been appointed as
corporate Controller; Ms. Lei previously held a management position
at KPMG LLP.
Additional
appointments:
William (Bill) Kanz has been appointed as Senior Vice
President, Engineering and Operations. In this role, Mr. Kanz will
lead the engineering, operations and manufacturing teams,
supporting Ondine's rapid commercial growth. Mr. Kanz is a
certified quality engineer and lean six-sigma black belt, and
brings a wealth of product management, manufacturing, and product
development expertise to the company. Building on his
operational management capabilities, he has developed some of the
world's leading atherectomy devices, ultrasound catheters and blood
pumps, and has 47 patents to his name.
Caetano Sabino, Ph.D. has been appointed as Ondine's
Director of Research and Development, building on his extensive
pharmaceutical sciences background and many years of development of
light-activated therapeutics. Dr. Sabino is an expert in
photodynamic disinfection, and has authored numerous important
publications, textbooks, and patents in the field. He most
recently held the position of CEO, BioLambda, Científica e
Comercial LTDA, Sao Paulo, Brazil manufacturing industrial
equipment for light-based disinfection in hospitals, clinics, and
the food industry.
Carolyn Cross, CEO, Ondine Biomedical
commented. "We will be providing an update on our upcoming
dual priorities of continued significant commercial expansion and
initiation of Phase 3 clinical trial in the USA with our partner,
HCA Healthcare."
*ENDS*
Enquiries:
Ondine
Biomedical
Inc.
|
|
Angelika Vance, Corporate
Communications
|
+001 (604) 838 2702
|
|
|
Singer Capital
Markets (Nominated Adviser and Joint Broker)
|
|
Aubrey Powell, Sam Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC Capital
Markets (Joint Broker)
|
|
Rupert Walford, Kathryn Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane
Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a
Canadian life science company innovating in the field of
photodisinfection therapies. Ondine has a pipeline of
investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Ondine's nasal photodisinfection technology is approved in several
jurisdictions under the brand name Steriwave®. It has been awarded
the CE mark and, in the US, has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA.
Products beyond nasal photodisinfection include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other
indications.